Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2006

View Archived Issues

Targeting kallikrein for CPB in the neonate

New compound targets leukocyte elastase and demonstrates antiinflammatory activity

New compound targets glia and modulates progression of AD

Caspase inhibition may lower the risk of AD post-TBI

New agents for treating endocrine-related disorders disclosed in patent literature

Novel agents claimed for thrombotic disorders in recent Daiichi patent

Recent Tanabe patent reports new treatments for urological disorders

Fast track designation for Surfaxin in bronchopulmonary dysplasia

European orphan drug status for Intercell's Japanese encephalitis vaccine

Labopharm's once-daily tramadol NDA accepted for review

Xibrom approved for treatment of pain following cataract surgery

PTC-124 studied in new phase II trial for Duchenne muscular dystrophy

Hematide begins phase II study to treat anemia in cancer patients

NDA for NRP-104 accepted for review

Phase III study of ICA-17043 in sickle cell anemia cleared to continue

IND for ADL-5859 placed on hold

Inspire preparing to advance denufosol tetrasodium into phase III CF program

AEterna Zentaris regains rights to cetrorelix for BPH

CRx-102 shows statistically significant improvement in pain in hand osteoarthritis

Tamiflu approved in Europe for flu prevention in children aged 1 to 12 years

Naglazyme approved in Europe for MPS VI

CE Mark for Xience V stent

Fast track designation for HCV protease inhibitor SCH-503034

FDA approval for HepaGam B

MAA filing for FK-506 Modified Release Formulation

Japanese filing for YM-060 in d-IBS

Hemopure sales commence in South Africa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...